Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free AEON Stock Alerts

AEON Biopharma (AEON) Competitors

AEON Biopharma logo
$0.28 +0.00 (+1.66%)
Closing price 03:59 PM Eastern
Extended Trading
$0.28 +0.00 (+1.05%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AEON vs. TVGN, BCTX, ALGS, IZTC, and KYNB

Should you buy AEON Biopharma stock or one of its competitors? AEON Biopharma's main competitors and comparable companies include Tevogen Bio (TVGN), Briacell Therap (BCTX), Aligos Therapeutics (ALGS), Invizyne Technologies (IZTC), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AEON Biopharma compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Tevogen Bio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tevogen BioN/AN/A-$26.27M-$4.61N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

Company Net Margins Return on Equity Return on Assets
Tevogen BioN/A N/A -472.77%
AEON Biopharma N/A N/A -994.63%

Tevogen Bio presently has a consensus target price of $100.00, indicating a potential upside of 1,355.60%. AEON Biopharma has a consensus target price of $1.10, indicating a potential upside of 299.85%. Given Tevogen Bio's higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

22.8% of AEON Biopharma shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, AEON Biopharma had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 3 mentions for AEON Biopharma and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.87 beat AEON Biopharma's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company Overall Sentiment
Tevogen Bio Very Positive
AEON Biopharma Neutral

Tevogen Bio has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Summary

Tevogen Bio and AEON Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to Briacell Therap?

AEON Biopharma (NASDAQ:AEON) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

AEON Biopharma's return on equity of 0.00% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Briacell Therap N/A -153.53%-129.26%

AEON Biopharma presently has a consensus price target of $1.10, indicating a potential upside of 299.85%. Given AEON Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe AEON Biopharma is more favorable than Briacell Therap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Briacell Therap is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
Briacell TherapN/AN/A-$26.31M-$7.92N/A

In the previous week, AEON Biopharma had 2 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for AEON Biopharma and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 1.87 beat AEON Biopharma's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the news media.

Company Overall Sentiment
AEON Biopharma Neutral
Briacell Therap Very Positive

AEON Biopharma has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

AEON Biopharma beats Briacell Therap on 9 of the 13 factors compared between the two stocks.

How does AEON Biopharma compare to Aligos Therapeutics?

AEON Biopharma (NASDAQ:AEON) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

AEON Biopharma has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. AEON Biopharma's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Aligos Therapeutics -241.01%-160.72%-92.30%

In the previous week, Aligos Therapeutics had 13 more articles in the media than AEON Biopharma. MarketBeat recorded 16 mentions for Aligos Therapeutics and 3 mentions for AEON Biopharma. Aligos Therapeutics' average media sentiment score of 0.25 beat AEON Biopharma's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AEON Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aligos Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aligos Therapeutics has higher revenue and earnings than AEON Biopharma. Aligos Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
Aligos Therapeutics$2.19M19.63-$24.19M-$7.30N/A

AEON Biopharma presently has a consensus price target of $1.10, indicating a potential upside of 299.85%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 458.78%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

AEON Biopharma has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Summary

Aligos Therapeutics beats AEON Biopharma on 11 of the 16 factors compared between the two stocks.

How does AEON Biopharma compare to Invizyne Technologies?

AEON Biopharma (NASDAQ:AEON) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
Invizyne TechnologiesN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Invizyne Technologies N/A N/A N/A

22.8% of AEON Biopharma shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AEON Biopharma had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for AEON Biopharma and 0 mentions for Invizyne Technologies. AEON Biopharma's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company Overall Sentiment
AEON Biopharma Neutral
Invizyne Technologies Neutral

AEON Biopharma currently has a consensus target price of $1.10, indicating a potential upside of 299.85%. Given AEON Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

AEON Biopharma beats Invizyne Technologies on 6 of the 7 factors compared between the two stocks.

How does AEON Biopharma compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Kyntra Bio presently has a consensus price target of $32.50, indicating a potential upside of 360.99%. AEON Biopharma has a consensus price target of $1.10, indicating a potential upside of 299.85%. Given Kyntra Bio's higher possible upside, equities analysts clearly believe Kyntra Bio is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Kyntra Bio has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 9.4% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyntra Bio$6.44M4.43$183.45M$40.460.17
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

Kyntra Bio has a net margin of 2,199.13% compared to AEON Biopharma's net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
Kyntra Bio2,199.13% N/A -45.24%
AEON Biopharma N/A N/A -994.63%

In the previous week, Kyntra Bio had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for AEON Biopharma. Kyntra Bio's average media sentiment score of 0.55 beat AEON Biopharma's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyntra Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AEON Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Kyntra Bio beats AEON Biopharma on 11 of the 15 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEON vs. The Competition

Export
MetricAEON BiopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6.96M$3.74B$7.06B$13.10B
Dividend YieldN/A3.69%2.57%10.45%
P/E Ratio1.5310.67269.0625.28
Price / SalesN/A1,294.08602.4391.76
Price / CashN/A102.8870.4850.90
Price / Book-0.0716.7812.916.24
Net Income-$36.63M-$13.32M$3.45B$347.60M
7 Day Performance-0.72%1.74%1.12%1.07%
1 Month Performance-22.94%1.60%1.79%1.03%
1 Year Performance-64.73%56.43%67.69%20.77%

AEON Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEON
AEON Biopharma
2.5755 of 5 stars		$0.28
+1.7%		$1.10
+299.9%		-66.2%$6.96MN/A1.535
TVGN
Tevogen Bio
1.7971 of 5 stars		$7.00
-0.3%		$100.00
+1,328.6%		-87.0%$29.54MN/AN/A3
BCTX
Briacell Therap
0.9597 of 5 stars		$3.39
+0.7%		N/A-52.5%$29.45MN/AN/A8
ALGS
Aligos Therapeutics
2.5373 of 5 stars		$4.75
+3.3%		$38.50
+710.5%		-11.5%$29.40M$2.19MN/A90
IZTC
Invizyne Technologies
N/A$4.60
-1.1%		N/A-42.6%$28.76MN/AN/A29

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel